Johnson & Johnson (JNJ) — closed signal from April 15, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 14, 2026 — +6.8% at the close.
Predicted vs. what happened
What happened
Reached its target in 75 days.
The thesis — published April 15, 2026
We see J&J as a steadier short-term holding because recent results showed stronger sales, management raised the full-year outlook, and the dividend was increased. Momentum is coming from cancer treatments and newer products, and shares are not as crowded as many fast-growing large caps. Upside is smaller, but downside appears better protected.
Primary drivers
- Raised outlook and a bigger dividend improve visibility
- Momentum from oncology and newer product sales
- Shares are trading from a less crowded position
- Stable cash flow offsets riskier growth names
How it played out
JNJ: target reached in 75 days
Lyra published an 8% growth thesis from a price of $237.76, with a target of $256.78. The thesis pointed to stronger sales, a raised full-year outlook, a larger dividend, momentum from oncology and newer products, a less crowded position, and stable cash flow.
JNJ reached the target in 75 days. It peaked at $269.43 on July 7, a 13.3% gain, then ended the window at $253.85. The peak exceeded both the expected growth and the target, although the closing price was below the target. The thesis played out.
What happened during the window
On June 8, 2026, Johnson & Johnson announced an agreement to acquire Firefly Bio for $1 billion in cash and add its oncology platform.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.